An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1).

Trial Profile

An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2015

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C; HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 03 Mar 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 18 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 10 Jan 2014 Planned End Date changed from 1 Sep 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top